secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001140361-26-004927
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Grace Therapeutics reports Q3 FY2026 net loss of $2.3M; cash $18.7M; FDA PDUFA date April 23, 2026 for GTx-104
--------------------------------------------------------------------------------

- Net loss of $2.3M ($0.14 per share) improved from $4.2M loss ($0.36 per share) in prior year quarter.
- FDA set April 23, 2026 as PDUFA target date for GTx-104 NDA for aSAH treatment.
- Cash and equivalents $18.7M as of Dec 31, 2025; company believes sufficient for 12+ months.
- Phase 3 STRIVE-ON trial data presented; GTx-104 showed 19% reduction in hypotension vs. oral nimodipine.
- Raised $4.0M through warrant exercises at $3.003/share; 1.35M shares issued.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000114036126004927/0001140361-26-004927-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000114036126004927/ef20064916_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-004927

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer